GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Cyclically Adjusted Price-to-FCF

Novavax (Novavax) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Novavax Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novavax Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Novavax's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Cyclically Adjusted Price-to-FCF Chart

Novavax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novavax Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Novavax's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Novavax's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted Price-to-FCF falls into.



Novavax Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Novavax's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Novavax's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.5/129.4194*129.4194
=-1.500

Current CPI (Dec. 2023) = 129.4194.

Novavax Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -2.041 99.695 -2.650
201406 -1.096 100.560 -1.411
201409 -1.587 100.428 -2.045
201412 -1.857 99.070 -2.426
201503 -2.931 99.621 -3.808
201506 -1.246 100.684 -1.602
201509 -2.444 100.392 -3.151
201512 -4.400 99.792 -5.706
201603 -5.578 100.470 -7.185
201606 -4.990 101.688 -6.351
201609 -4.893 101.861 -6.217
201612 -4.996 101.863 -6.348
201703 -3.325 102.862 -4.183
201706 -0.962 103.349 -1.205
201709 -3.063 104.136 -3.807
201712 -2.785 104.011 -3.465
201803 -3.931 105.290 -4.832
201806 -2.143 106.317 -2.609
201809 -1.774 106.507 -2.156
201812 -2.389 105.998 -2.917
201903 -2.515 107.251 -3.035
201906 -1.299 108.070 -1.556
201909 -1.341 108.329 -1.602
201912 -0.852 108.420 -1.017
202003 -0.523 108.902 -0.622
202006 1.908 108.767 2.270
202009 -0.247 109.815 -0.291
202012 -2.593 109.897 -3.054
202103 8.890 111.754 10.295
202106 1.744 114.631 1.969
202109 -2.065 115.734 -2.309
202112 -4.740 117.630 -5.215
202203 -1.305 121.301 -1.392
202206 -2.502 125.017 -2.590
202209 -0.872 125.227 -0.901
202212 -1.752 125.222 -1.811
202303 -4.052 127.348 -4.118
202306 -1.727 128.729 -1.736
202309 -0.561 129.860 -0.559
202312 -1.500 129.419 -1.500

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novavax  (NAS:NVAX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Novavax Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Novavax's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax (Novavax) Business Description

Industry
Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Executives
Filip Dubovsky officer: President, R&D C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn officer: President, R&D 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara officer: EVP, Chief Strategy Officer 333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs director, officer: President and CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii officer: SVP, General Counsel C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck director, officer: President and CEO 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino officer: SVP, CBO and CFO 9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly officer: EVP, CFO and Treasurer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans director 1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr director 241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100